A Phase 1 interventional study of VIB4920 and Placebo in Adult Onset Rheumatoid Arthritis, sponsored by Amgen. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is the 37th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 52nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–75
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 17 · Phase 4 12
First in 1997; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 211 across the 47 interventional studies, 2,522 across the 4 observational. Of the 56 that completed or were terminated, 30 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).
Study with completed results acquired from Horizon in 2024. Originally Viela Bio was the sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
Other: Placebo
Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
Drug: VIB4920
Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
Drug: VIB4920
Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
Drug: VIB4920
Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
Drug: VIB4920
Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
Also known as: MEDI4920
Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through Day 169
Number of Participants With Treatment-emergent AEs of Special Interests (AESIs)
An AESI (serious or non-serious) is one of scientific and medical interest specific to understanding of study drug and may have required close monitoring, collection of additional information by investigator and rapid communication by investigator to the sponsor.
Time frame: Day 1 through Day 169
Maximum Observed Plasma Concentration (Cmax) of VIB4920
Maximum observed plasma concentration (Cmax) of VIB4920 is reported.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Time to Maximum Plasma Concentration (Tmax) of VIB4920
Time to maximum plasma concentration (Tmax) of VIB4920 is reported.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Area Under the Plasma Concentration Time Curve of the Dosing Interval (AUCtau) of VIB4920
Area under the plasma concentration time curve of the dosing interval (AUCtau) of VIB4920 is reported.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Dose Normalized AUCtau of VIB4920
Dose normalized AUCtau of VIB4920 is reported. Dose normalized AUCtau is calculated by dividing AUCtau by the dose of administered VIB4920 (in mg).
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Area Under the Plasma Concentration Time Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of VIB4920
Area under the plasma concentration time curve from time zero to extrapolated infinite time (AUC0-inf) of VIB4920 is reported.
Time frame: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Systemic Clearance (CL) of VIB4920
Systemic clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Terminal Elimination Half-life (t½) of VIB4920
Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Volume of Distribution at Steady State (Vss) of VIB4920
Volume of distribution at steady state (Vss) of VIB4920 is reported.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Accumulation Ratio (AR) of VIB4920
Accumulation ratio of VIB4920 is reported. Accumulation ratio was determined using AUCtau, Dose 7/AUCtau, Dose 1.
Time frame: Dose 1: Post-dose (end of infusion) on Day 1, pre-dose on Day 15; Dose 7: Pre- and post-dose (end of infusion) on Day 85; and on Days 92, 99, 113, 141, and 169
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to VIB4920
The number of participants with positive antibodies to VIB4920 are reported.
Time frame: Pre-dose on Days 1, 29, 57, and 85; and on Days 141, and 169
The study was conducted from 12 May 2016 to 09 Aug 2018 in Poland and the United States of America.
| Milestone | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|---|
| Started | 15 | 8 | 10 | 12 | 12 |
| Completed | 14 | 6 | 10 | 12 | 12 |
| Not completed | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|---|
| TEAEs | 13 | 3 | 7 | 6 | 10 |
| TESAEs | 0 | 0 | 0 | 0 | 1 |
An AESI (serious or non-serious) is one of scientific and medical interest specific to understanding of study drug and may have required close monitoring, collection of additional information by investigator and rapid communication by investigator to the sponsor.
| Participants | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|---|
| Encephalitis | 0 | 0 | 0 | 0 | 1 |
| Herpes simplex | 0 | 0 | 0 | 0 | 1 |
| Oral herpes | 0 | 0 | 0 | 1 | 0 |
Maximum observed plasma concentration (Cmax) of VIB4920 is reported.
| µg/mL | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 20.6 ± 5.26 | 158 ± 95.4 | 392 ± 84.4 | 360 ± 83.8 |
| Dose 7 | 24.4 ± 3.72 | 157 ± 40.7 | 423 ± 114 | 627 ± 159 |
Time to maximum plasma concentration (Tmax) of VIB4920 is reported.
| Days | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 0.02 (0.02 to 1.00) | 0.04 (0.04 to 0.04) | 0.06 (0.06 to 1.00) | 0.06 (0.06 to 0.06) |
| Dose 7 | 0.02 (0.02 to 0.02) | 0.04 (0.04 to 0.04) | 0.06 (0.06 to 0.06) | 0.06 (0.06 to 0.06) |
Area under the plasma concentration time curve of the dosing interval (AUCtau) of VIB4920 is reported.
| µg*day/mL | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 122 ± 25.5 | 669 ± 164 | 2150 ± 496 | 2360 ± 466 |
| Dose 7 | 262 ± 94.7 | 1430 ± 466 | 3760 ± 1370 | 5850 ± 1530 |
Dose normalized AUCtau of VIB4920 is reported. Dose normalized AUCtau is calculated by dividing AUCtau by the dose of administered VIB4920 (in mg).
| µg*day/mL/mg | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 1.62 ± 0.341 | 1.34 ± 0.328 | 2.15 ± 0.496 | 1.58 ± 0.311 |
| Dose 7 | 3.49 ± 1.26 | 2.87 ± 0.931 | 3.76 ± 1.37 | 3.90 ± 1.02 |
Area under the plasma concentration time curve from time zero to extrapolated infinite time (AUC0-inf) of VIB4920 is reported.
| µg*day/mL | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of VIB4920 | 163 ± 42.7 | 824 ± 228 | 2660 ± 744 | 3480 ± 842 |
Systemic clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
| mL/day | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 489 ± 135 | 654 ± 203 | 405 ± 120 | 457 ± 120 |
| Dose 7 | 449 ± 129 | 536 ± 152 | 421 ± 107 | 381 ± 94.8 |
Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the plasma.
| Days | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 6.25 ± 1.26 | 5.61 ± 0.891 | 6.12 ± 0.725 | 8.70 ± 2.61 |
| Dose 7 | 7.82 ± 1.50 | 9.58 ± 1.57 | 9.72 ± 1.32 | 9.58 ± 1.37 |
Volume of distribution at steady state (Vss) of VIB4920 is reported.
| mL | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Dose 1 | 4230 ± 595 | 5040 ± 1220 | 3510 ± 844 | 5380 ± 1210 |
| Dose 7 | 5060 ± 980 | 5600 ± 1010 | 4620 ± 1060 | 4100 ± 905 |
Accumulation ratio of VIB4920 is reported. Accumulation ratio was determined using AUCtau, Dose 7/AUCtau, Dose 1.
| Ratio | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Accumulation Ratio (AR) of VIB4920 | 1.51 ± 0.265 | 1.51 ± 0.287 | 1.20 ± 0.251 | 1.76 ± 0.305 |
The number of participants with positive antibodies to VIB4920 are reported.
| Participants | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|
| Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to VIB4920 | 3 | 3 | 1 | 0 |
Collected over Day 1 through Day 169. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| VIB4920 75 mg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| VIB4920 500 mg | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| VIB4920 1000 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| VIB4920 1500 mg | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Event | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|---|
| EncephalitisInfections and infestations | 0/15 | 0/8 | 0/10 | 0/12 | 1/12 |
| Event | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/15 | 0/8 | 1/10 | 2/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 2/8 | 1/10 | 0/12 | 0/12 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/15 | 0/8 | 0/10 | 0/12 | 3/12 |
| Urinary tract infectionInfections and infestations | 0/15 | 0/8 | 0/10 | 0/12 | 3/12 |
| NasopharyngitisInfections and infestations | 1/15 | 0/8 | 2/10 | 0/12 | 0/12 |
| DizzinessNervous system disorders | 0/15 | 0/8 | 2/10 | 0/12 | 0/12 |
| Alanine aminotransferase increasedInvestigations | 0/15 | 0/8 | 0/10 | 1/12 | 2/12 |
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 0/8 | 0/10 | 0/12 | 2/12 |
| Acute sinusitisInfections and infestations | 2/15 | 0/8 | 0/10 | 0/12 | 1/12 |
| FatigueGeneral disorders | 2/15 | 0/8 | 0/10 | 1/12 | 0/12 |
Intent-to treat population included all randomized and treated participants, grouped according to assigned treatment.
| Age, Continuous(years) | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 58.3 ± 8.0 | 57.9 ± 7.4 | 53.7 ± 9.8 | 52.1 ± 11.5 | 50.9 ± 8.6 | 54.6 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 6 | 6 | 10 | 10 | 46 |
| Male | 1 | 2 | 4 | 2 | 2 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 1 | 1 | 0 | 7 |
| Not Hispanic or Latino | 12 | 6 | 9 | 11 | 12 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | VIB4920 75 mg | VIB4920 500 mg | VIB4920 1000 mg | VIB4920 1500 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 2 | 0 | 5 |
| White | 13 | 8 | 9 | 10 | 12 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in May 2018, 24 months.
Results were first posted in Sep 2019, 1 year 3 months after primary completion.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 24 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazodalibep